Bone marrow suppression is a virtually ubiquitous side effect of chemotherapy that limits the dose of the chemo drug. However, a new drug, trilaciclib, can make this a problem of the past. The drug, trade name Cosela, is being developed by G1 Theraputics, and has already been approved for use by the FDA for patients with extensive-stage small cell lung cancer under chemotherapy treatment.
The company G1 Theraputics, based in North Carolina, is having a summit on April 9, 2021 to review and prepare strategies for the launch of Cosela in the U.S. market (1). The small molecule functionally freezes Hematopoietic Stem and Progenitor Cells (HSPCs) in the G1 cell cycle phase (2). This leads to a decrease of myelosuppression when administered before the chemotherapy, clinical studies shown. This protects blood cell lineages and helps the bone marrow mass to stay healthy and prevent decrease. As the bone marrow mass is so detrimental and causes much of the dreaded side-effects of chemotherapy, the launch of Cosela can be vital in bettering the quality of life in chemotherapy patients in the near future.
By: Pavle Mihajlovic